Eaton Vance Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Eaton Vance Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,803	Closed	-$930K	–	1759
2022 Q1	$930K	Buy	12,803 +12,103	+1,729%	+$842K	﹤0.01%	1380
2021 Q4	$59K	Hold	700	–	–	﹤0.01%	2036
2021 Q3	$63K	Hold	700	–	–	﹤0.01%	1496
2021 Q2	$67K	Sell	700 -75	-10%	-$7.81K	﹤0.01%	2057
2021 Q1	$88K	Buy	+775	New	+$106K	﹤0.01%	1639

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Eaton Vance Management's RARE Position: Q2 2022 in Review

Eaton Vance Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 12,803 shares — an estimated $930K sold.

Eaton Vance Management first reported a position in RARE in Q1 2021 and held it in 5 quarters. The position peaked at $930K in Q1 2022. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

Eaton Vance Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Eaton Vance Management sold 12,803 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $930K.
Eaton Vance Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 5 quarters.
Eaton Vance Management's Ultragenyx Pharmaceutical position peaked at $930K in Q1 2022.
223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.